You are here: Industry Insights > autoimmune

News List

InflaRx snags $55M for inflammatory, autoimmune trials fiercebiotech
October 16, 2017
InflaRx has raised $55 million (€47 million) in a new funding round. The series D follows fast after InflaRx established the potential of its anti-human complement factor C5a monoclonal antibody IFX-1 with phase 2a data.
Lilly, Nektar to co-develop new immunotherapy pharmatimes
July 26, 2017
Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million.
FDA Grants Priority Review for Genentech’s Actemra® sBLA for Giant Cell Arteritis, a Form of Vasculi americanpharmaceuticalreview
January 25, 2017
Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Supplemental Biologics License Application (sBLA) for Actemra® (tocilizumab) for the treatment of GCA, a chronic, potentially life-threatening autoimmune condi
Connect Biopharmaceuticals Completes $25 Million Financing to Advance Clinical Development of Novel firstwordpharma
January 25, 2017
Connect Biopharmaceuticals, Ltd., a clinical-stage company that discovers and develops novel immune modulators for the treatment of autoimmune diseases and cancer, today announces the completion of a $20 million Series A financing.

Previous page 1 2 Next page